Experimental brain cancer therapy infused directly into tumors shows promise in early trial
NCT ID NCT02303678
First seen Mar 07, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This early-phase study tested a new drug called D2C7-IT for people with recurrent malignant glioma, a serious brain cancer. The drug was delivered directly into the tumor through tiny tubes over 72 hours. The main goal was to find the safest dose and see if it could help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Preston Robert Tisch Brain Tumor Center at Duke
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.